UNMC_Acronym_Vert_sm_4c
University of Nebraska Medical Center

Category: Long COVID

Are Subphenotypes for Long COVID Beneficial?

(MedPageToday) A recent study opens in a new tab or window published in Nature Medicine, “Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes” by Hao Zhang, PhD, et al. used a data-driven framework to stratify patients suffering with post-acute SARS-CoV-2 (PASC), also referred to as long COVID, into different subcategories of sequelae. The bulk of the patients in the […]

Dec 20, 2022

Scientists’ understanding of long covid is improving

(Economist) PODCAST Our podcast on science and technology. This week, we examine the latest research into what may be causing long covid, and ask whether the hunt for answers could shed light on other chronic conditions. SOON AFTER the pandemic began, another health crisis started to emerge. Long covid now affects millions of people around the world. […]

Dec 13, 2022

New VA study finds Paxlovid may cut the risk of long COVID

(NPR) It’s well-documented that Paxlovid — a 5-day course of antiviral pills from Pfizer — can reduce the risk of hospitalization in COVID-19 patients who are more likely to develop severe illness. Now, researchers from the Veterans Health Administration find that taking the medication may also reduce the risks of later developing long COVID, according […]

Nov 8, 2022

Pfizer’s Paxlovid Antiviral Lowered Long-Covid Risk in Study

(Bloomberg) Pfizer Inc.’s blockbuster Paxlovid antiviral that lowers rates of illness and death in people infected with the coronavirus also cuts the risk of some symptoms of disabling long Covid, a study found.Taking the oral medication within five days of testing positive for a SARS-CoV-2 infection was linked to a 26% lower risk of lingering […]

Nov 7, 2022

A Reporter in Search of Long Covid’s Impact

(Bloomberg Prognosis/Jason Gale) While the evidence is still emerging, what’s clear already is that the social and economic impacts are profound. Harvard economist David Cutler puts the cost of long Covid at $3.7 trillion in the US alone. And the condition could impair more than 140 million people worldwide. 

Nov 3, 2022

U.S. government to test Pfizer’s Paxlovid for long COVID

(Reuters) The U.S. National Institutes of Health’s $1 billion RECOVER Initiative has picked Pfizer Inc’s (PFE.N) antiviral drug Paxlovid as the first treatment it will study in patients with long COVID, organizers of the study said on Thursday. The complex medical condition involves more than 200 symptoms ranging from exhaustion and cognitive impairment to pain, fever and […]

Oct 28, 2022

Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study

(Nature) The immune-inflammatory response during the acute phase of COVID-19, as assessed using peak body temperature (PBT) and peripheral oxygen saturation (SpO2), predicts the severity of chronic fatigue, depression and anxiety symptoms 3–4 months later.

Oct 24, 2022

Dr Anthony Fauci: long Covid is an ‘insidious’ public health emergency

Guardian – Dr. Fauci urged US Congress to avoid complacency and resume funding to combat the virus as well as long Covid, a chronic and prolonged illness that continues to elude scientists and healthcare providers. “It’s a very insidious beneath-the-radar-screen public health emergency,” Fauci said via Zoom. “It isn’t that you have people who are […]

Oct 18, 2022

Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study

Nature – With increasing numbers infected by SARS-CoV-2, understanding long-COVID is essential to inform health and social care support. A Scottish population cohort of 33,281 laboratory-confirmed SARS-CoV-2 infections and 62,957 never-infected individuals were followed-up via 6, 12 and 18-month questionnaires and linkage to hospitalization and death records. Of the 31,486 symptomatic infections,1,856 (6%) had not […]

Oct 13, 2022

Use of Cardiopulmonary Exercise Testing to Evaluate Long COVID-19 Symptoms in Adults

JAMA – In this systematic review and meta-analysis of 38 studies comprising 2160 participants, exercise capacity was reduced by 4.9 mL/kg/min among individuals with symptoms consistent with LC compared with individuals without symptoms more than 3 months after SARS-CoV-2 infection. Findings among individuals with exertional intolerance suggest that deconditioning, dysfunctional breathing, chronotropic incompetence, and abnormal […]

Oct 13, 2022